Get started
REGENERON PHARMACEUTICALS INC COM STK USD0.001REGENERON PHARMACEUTICALS INC COM STK USD0.001REGENERON PHARMACEUTICALS INC COM STK USD0.001

REGENERON PHARMACEUTICALS INC COM STK USD0.001

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

0R2M chart


Full chart

Key facts today


Cantor Fitzgerald cut its price target for Regeneron Pharmaceuticals to $800 from $1,015, keeping a neutral rating. Analysts report an average overweight rating, with a mean price target of $974.65.
Regeneron Pharmaceuticals is set to announce its latest financial results before the market opens on Tuesday.
Analyze the impactAnalyze the impact

0R2M upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪73.95 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
17.0
Basic EPS (TTM)
43.2 USD
Net income (FY)
‪3.95 B‬ USD
Revenue (FY)
‪13.12 B‬ USD
Shares float
‪105.91 M‬
Beta (1Y)
0.82

Employees


Employees (FY)
‪13.45 K‬
Change (1Y)
‪+1.6 K‬ +13.49%
Revenue / Employee (1Y)
‪975.26 K‬ USD
Net income / Employee (1Y)
‪293.95 K‬ USD

About Regeneron Pharmaceuticals, Inc.


Sector
Health Technology
CEO
Leonard S. Schleifer
Headquarters
Tarrytown
Website
regeneron.com
Founded
1988
FIGI
BBG00JRY9CR9
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

0R2M news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

0R2M highest yielding bonds


REGN5027988
Regeneron Pharmaceuticals, Inc. 2.8% 15-SEP-2050
Yield to maturity
7.53%
Maturity date
Sep 15, 2050
REGN5027987
Regeneron Pharmaceuticals, Inc. 1.75% 15-SEP-2030
Yield to maturity
5.62%
Maturity date
Sep 15, 2030

Explore more bonds 

Sparks


Curated watchlists where 0R2M is featured.

See all sparks 

Frequently Asked Questions


The current price of 0R2M is 696.6 USD — it has decreased by −2.02% in the past 24 hours. Watch REGENERON PHARMACEUTICALS INC COM STK USD0.001 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange REGENERON PHARMACEUTICALS INC COM STK USD0.001 stocks are traded under the ticker 0R2M.
0R2M stock has risen by 0.74% compared to the previous week, the month change is a −6.37% fall, over the last year REGENERON PHARMACEUTICALS INC COM STK USD0.001 has showed a −25.09% decrease.
We've gathered analysts' opinions on REGENERON PHARMACEUTICALS INC COM STK USD0.001 future price: according to them, 0R2M price has a max estimate of 1,200.00 USD and a min estimate of 565.00 USD. Watch 0R2M chart and read a more detailed REGENERON PHARMACEUTICALS INC COM STK USD0.001 stock forecast: see what analysts think of REGENERON PHARMACEUTICALS INC COM STK USD0.001 and suggest that you do with its stocks.
0R2M reached its all-time high on Aug 27, 2024 with the price of 1,211.0 USD, and its all-time low was 274.2 USD and was reached on Oct 3, 2019. View more price dynamics on 0R2M chart.
See other stocks reaching their highest and lowest prices.
0R2M stock is 10.23% volatile and has beta coefficient of 0.82. Track REGENERON PHARMACEUTICALS INC COM STK USD0.001 stock price on the chart and check out the list of the most volatile stocks — is REGENERON PHARMACEUTICALS INC COM STK USD0.001 there?
Today REGENERON PHARMACEUTICALS INC COM STK USD0.001 has the market capitalization of ‪73.28 B‬, it has increased by 0.93% over the last week.
Yes, you can track REGENERON PHARMACEUTICALS INC COM STK USD0.001 financials in yearly and quarterly reports right on TradingView.
REGENERON PHARMACEUTICALS INC COM STK USD0.001 is going to release the next earnings report on May 1, 2025. Keep track of upcoming events with our Earnings Calendar.
0R2M earnings for the last quarter are 12.07 USD per share, whereas the estimation was 11.35 USD resulting in a 6.37% surprise. The estimated earnings for the next quarter are 10.22 USD per share. See more details about REGENERON PHARMACEUTICALS INC COM STK USD0.001 earnings.
REGENERON PHARMACEUTICALS INC COM STK USD0.001 revenue for the last quarter amounts to ‪3.79 B‬ USD, despite the estimated figure of ‪3.74 B‬ USD. In the next quarter, revenue is expected to reach ‪3.47 B‬ USD.
0R2M net income for the last quarter is ‪1.34 B‬ USD, while the quarter before that showed ‪1.43 B‬ USD of net income which accounts for −6.40% change. Track more REGENERON PHARMACEUTICALS INC COM STK USD0.001 financial stats to get the full picture.
No, 0R2M doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 4, 2025, the company has ‪13.45 K‬ employees. See our rating of the largest employees — is REGENERON PHARMACEUTICALS INC COM STK USD0.001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. REGENERON PHARMACEUTICALS INC COM STK USD0.001 EBITDA is ‪4.61 B‬ USD, and current EBITDA margin is 36.36%. See more stats in REGENERON PHARMACEUTICALS INC COM STK USD0.001 financial statements.
Like other stocks, 0R2M shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade REGENERON PHARMACEUTICALS INC COM STK USD0.001 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So REGENERON PHARMACEUTICALS INC COM STK USD0.001 technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating REGENERON PHARMACEUTICALS INC COM STK USD0.001 stock shows the sell signal. See more of REGENERON PHARMACEUTICALS INC COM STK USD0.001 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.